[Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (AMR Alliance Japan, March 7, 2022)
date : 3/7/2022
Tags: AMR
![[Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (AMR Alliance Japan, March 7, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-case06-top_ENG.jpg)
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital) and Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) reports a case titled “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis.”
This is the second of two case studies from AMR Alliance Japan on the usefulness of TDM for antimicrobial stewardship.
Case study 06
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis.”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
Case study 05
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
![[AMR Case Study 06] Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis](/assets/img/katsudo/icon_pdf_l.png){kind=icon}
Top Research & Recommendations Posts
- [Survey Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Preliminary Version) (September 11, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022）
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Three Necessary Perspectives for Formulating the Basic Plan for the Promotion of Policies on Dementia: Creating a Society That is Inclusive for All People at All Times (April 1, 2024)
- [Policy Recommendations] Dementia Policy for an Inclusive Society 2024: HGPI Recommendations on The Basic Plan on Dementia to Promote an Inclusive Society (Draft) and Basic Measures (Draft) (August 13, 2024)
Featured Posts
-
2024-07-03
[Japanese Version Release] “Call for Actionable Steps in Response to the Rising Threat of Antimicrobial Resistance (AMR)” (July 3, 2024)
![[Japanese Version Release] “Call for Actionable Steps in Response to the Rising Threat of Antimicrobial Resistance (AMR)” (July 3, 2024)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20240628_Call-for-Actionable-Steps-in-Response-to-the-Rising-Threat-of-AMR.jpg)
-
2024-09-26
[Event Report] UN General Assembly High-Level Meeting on AMR Side Event “Global Action on AMR: Advancing Healthy Longevity and Sustainability under UHC” (September 25, 2024, New York City, USA)
![[Event Report] UN General Assembly High-Level Meeting on AMR Side Event “Global Action on AMR: Advancing Healthy Longevity and Sustainability under UHC” (September 25, 2024, New York City, USA)](https://hgpi.org/en/wp-content/uploads/sites/2/AMR_NY.png)
-
2024-09-26
[Registration Open] HGPI Salon Special Edition “The 2024 U.S. Presidential Election’s Impact on Japan’s Healthcare Policies: Future Implications for U.S.-China Relations and U.S.-Japan Cooperation” (October 28, 2024)
![[Registration Open] HGPI Salon Special Edition “The 2024 U.S. Presidential Election’s Impact on Japan’s Healthcare Policies: Future Implications for U.S.-China Relations and U.S.-Japan Cooperation” (October 28, 2024)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI-salon_20241028-topr.png)
-
2024-09-27
[HGPI Policy Column] (No. 48) From the Meaningful Involvement Promotion Project: The Resolution on Social Participation at the 77th World Health Assembly
![[HGPI Policy Column] (No. 48) From the Meaningful Involvement Promotion Project: The Resolution on Social Participation at the 77th World Health Assembly](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20240924_PPI_HGPI-Policy-Column.jpg)
-
2024-10-01
[Event Report] Online Information Session for Japan’s Patient Expert Platform (J-PEP), a Members Only Website (September 6, 2024)
![[Event Report] Online Information Session for Japan’s Patient Expert Platform (J-PEP), a Members Only Website (September 6, 2024)](https://hgpi.org/en/wp-content/uploads/sites/2/HGPI_20240816_Online-Information-Session-for-Japans-Patient-Expert-Platform-1.png)
